- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03897114
Cocoa Intake for Health Promotion in Athletes (INDYCA)
Cocoa Intake for the Prevention of Gastrointestinal Problems in Athletes: Effects on Oxidative Stress, Inflammation, Microbiota and Sports Performance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of this project is to investigate the benefits of daily consumption of cocoa in endurance athletes in:
A) Gastrointestinal problems associated with exercise. B) Reinforcement of the gastrointestinal barrier. C) Parameters of inflammation and oxidative stress. D) Sports performance. E) Body composition
The starting hypothesis of this project is based on the fact that daily cocoa consumption could improve the gastrointestinal symptoms associated with resistance exercise. Cocoa decreases the symptoms associated with splenic hypovolemia and strengthens the gastrointestinal epithelial barrier increasing the presence of Lactobacillus spp. and Bifidobacterium spp. in the intestinal microbiota.
A randomized, blinded, parallel placebo controlled intervention study will be carried out in endurance athletes who train in the sports facilities of the European University of Madrid. The number of male athletes for the study will be 56 (28 in each experimental group), all of them aimed at competition with an age between 18 and 40 years and an aerobic power consumption of oxygen greater than or equal to 55 mL / kg / min). The calculation of the sample size has been made selecting with a significance level alpha = 0.05 and a power (beta) of 0.90 for a 2-tailed analysis, taking into account we want to detect a difference of at least 15% in the improvement of the gastrointestinal symptoms, that the standard detected deviation in the questionnaire to be used, in previous studies, is 1.5 points out of 9 and that the expected proportion of losses is 15%.
Before and after the intervention, the athletes will do a test in which we will measure their maximum aerobic capacity. This will be done in the facilities of Europea University of Madrid where there is available a rolling belt. Also, they will do a second test in which we will measure the time they spend running a kilometer at the maximum speed. Body composition will be evaluated by dual-energy X-ray absorptiometry (DEXA). Blood, urine and feces samples will be required before and after the physical tests. Blood and urine samples will be collected in the morning while the feces samples will be collected the day before. The biological samples will be frozen at -80ºC until analyses.
The intervention will be carried out for 10 weeks. Cocoa or placebo will be provide in a single daily intake of 5 g of cocoa containing 500 mg of flavanols (dose at which a prebiotic effect has been demonstrated) or 5 g of maltodextrin.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Madrid
-
Villaviciosa De Odón, Madrid, Spain, 28670
- Jose Ángel García Merino
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men.
- Age between 18 and 50 years
- Aerobic power of oxygen consumption greater than or equal to 55 mL / kg / min
Exclusion Criteria:
- Intake of antibiotics (3 months before the trial) or any chronical medication.
- Intake of probiotics, prebiotics or any type of food or ergogenic supplements.
- To be vegetarian or vegan
- Smoke.
- Have documented gastrointestinal diseases (ulcers, irritable bowel, ulcerative colitis, Crohn's disease, etc.).
- Previous gastrointestinal surgeries or any disease diagnosed at the time of inclusion in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cocoa group
The cocoa will be provided in sachets.
The intervention will be carried out for 10 weeks.
Cocoa is provided in a single daily dose of 5 g, which contains 83 mg of flavonoids per gram of cocoa (dose at which a prebiotic effect has been shown).
|
Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.
|
PLACEBO_COMPARATOR: Placebo group
Maltodextrin will be supplied as a placebo, which will be provided in sachets.
Athletes will take 5g of product per day.
|
The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of fat mass
Time Frame: Fat mass will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Energy X-ray absorptiometry (DEXA ).
|
Fat mass will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of lean mass
Time Frame: Lean mass will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Energy X-ray absorptiometry (DEXA ).
|
Lean mass will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Sport performance test.
Time Frame: Sport performance will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Assessment of maximal aerobic capacity.
|
Sport performance will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Sport performance test 2.
Time Frame: Sport performance will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Measurement of the time that the sportsmen spend running one kilometer at the maximum speed.
|
Sport performance will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention
|
Change in eating habits.
Time Frame: Lifestyle will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention.
|
Food Frequency Questionnaire.
|
Lifestyle will be analyzed at the beginning (baseline dose) and after 10 weeks of intervention.
|
Change in Gut Microbiota
Time Frame: Gut microbiota will be analyzed at the beginning (basiline dose) and after 10 weeks of intervention.
|
Determination of Microbial diversity by 16S rRNA Sequencing.
|
Gut microbiota will be analyzed at the beginning (basiline dose) and after 10 weeks of intervention.
|
Measurement of the parameters of inflammation.
Time Frame: Plasma cytokines will be analyzed at the beginning and at the end of the 10-week intervention.
|
Cytokines will be measured in plasma (IL-6, IL-10, IL-1β).
|
Plasma cytokines will be analyzed at the beginning and at the end of the 10-week intervention.
|
Indicators of gastrointestinal barrier.
Time Frame: Plasmatic LPS will be analyzed at the beginning and at the end of the 10-week intervention.
|
Determination of plasmatic lipopolysaccharide (LPS) levels as an indicator of bacterial translocation.
|
Plasmatic LPS will be analyzed at the beginning and at the end of the 10-week intervention.
|
Modification from baseline of gastrointestinal symptoms at 10 weeks
Time Frame: The questionnaire for the evaluation of gastrointestinal symptoms will be given to the athletes at the beginning and at the end of the 10-week intervention.
|
The evaluation of gastrointestinal symptoms will be carried out through following the questionnaire described by Pfeiffer et al. (2009).
|
The questionnaire for the evaluation of gastrointestinal symptoms will be given to the athletes at the beginning and at the end of the 10-week intervention.
|
Change from baseline of oxidative stress parameters .
Time Frame: Nitric oxide will be analyzed at the beginning and at the end of the 10-week intervention.
|
Nitric oxide levels will be measured in plasma and urine.
|
Nitric oxide will be analyzed at the beginning and at the end of the 10-week intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- AGL2016-77288-R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Cocoa group
-
Universidad Europea de MadridMinisterio de Economía y Competitividad, SpainCompleted
-
Instituto de Cardiologia do Rio Grande do SulNot yet recruitingSedentary BehaviorBrazil
-
Brigham and Women's HospitalMasterFoodsCompleted
-
University Rovira i VirgiliCompletedCardiovascular DiseasesSpain
-
Instituto Nacional de Perinatologia Isidro Espinosa...National Polytechnic Institute, MexicoNot yet recruitingMetabolic SyndromeMexico
-
University of NottinghamMars, Inc.CompletedDiabetesUnited Kingdom
-
Griffin HospitalBoston UniversityCompleted
-
Seoul National University HospitalCompleted
-
Technische Universität DresdenUniversity of WuerzburgUnknown
-
University of NottinghamThe Dunhill Medical TrustCompletedRegional Blood FlowUnited Kingdom